|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnostic performance of PON1 alone was comparable to that of the MPO/PON1 ratio for CAD risk assessment; however, MPO may increase the true positive rate.
|
30448568 |
2019 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we investigated whether salivary levels of MMP-9 and MPO corresponded to plasma levels in patients with coronary artery disease (CAD), both at rest and after acute physical exercise.
|
30726210 |
2019 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple lines of evidence suggest an association between MPO and cardiovascular disease (CVD) including coronary artery disease, congestive heart failure, arterial hypertension, pulmonary arterial hypertension, peripheral arterial disease, myocardial ischemia/reperfusion-related injury, stroke, cardiac arrhythmia and venous thrombosis.
|
30797769 |
2019 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data implicate MPO in atherosclerotic plaque instability and suggest that non-invasive imaging and pharmacological inhibition of plaque MPO activity hold promise for clinical translation in the management of high-risk coronary artery disease.
|
30219874 |
2018 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Design and methods We investigated whether the circulating neutrophil extracellular traps markers, double-stranded DNA and myeloperoxidase-DNA were associated with clinical outcome and hypercoagulability in patients with stable coronary artery disease.
|
29473463 |
2018 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.
|
29618370 |
2018 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloperoxidase (MPO) derived oxidants and HDL proteome changes are implicated in HDL dysfunction in subjects with CAD in the United States; however, the effect of MPO on HDL function and HDL proteome in ethnic Chinese population is unknown.
|
29505607 |
2018 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The A allele of MPO gene -463G/A polymorphism might protect the people from suffering the CAD risk.
|
28328864 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background Myeloperoxidase has shown potential as a marker for prognosis of coronary artery disease, but presently little is known about preanalytical handling of samples for quantifying myeloperoxidase.
|
27422133 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes the current knowledge about the role of MPO in CAD with a focus on its possible roles in plaque rupture and recent advances to quantify and image MPO in plasma and atherosclerotic plaques.
|
27884085 |
2017 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Regarding the 129G/A gene polymorphism, the pooled OR for the genotype AA + AG versus GG was 0.906 (95% CI = 0.74-1.10).This meta-analysis suggested an association between the MPO 463G/A polymorphism and the risk of CAD, but there is no significant association between the MPO 129G/A gene polymorphism and CAD risk.
|
28682877 |
2017 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we compared myeloperoxidase and protein-bound 3-chlorotyrosine (ClY) levels in subjects with varying degrees of CKD and tested their associations with CAD.
|
28668952 |
2017 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease.
|
26323267 |
2016 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MPO concentrations but not genetic variants at the MPO locus are independently associated with risk for total and cardiovascular mortality in coronary artery disease patients.
|
24746542 |
2014 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The clinical implications for CAD and a better understanding of the functional basis for the association of CFH and MPO variants with circulating MPO levels require further study.
|
23620142 |
2013 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was strong evidence for an association between the MPO G-463A polymorphism and CAD.
|
23583798 |
2013 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis demonstrated the evidence that there was no significant association between the MPO -463G/A polymorphism and the risk of CAD; larger and well-designed multicenter studies are needed to confirm our results.
|
24036021 |
2013 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of myeloperoxidase -463 G/A gene polymorphism and plasma levels on coronary artery disease.
|
20568015 |
2011 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found no association between MPO polymorphism and CAD severity, although a relation was observed for MPO plasma levels and extension of CAD.
|
19651119 |
2010 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease.
|
18440308 |
2008 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myeloperoxidase (MPO) is an inflammatory enzyme produced by activated leukocytes that predicts risk of coronary heart disease.
|
18514165 |
2008 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The -463G allele is linked to higher MPO expression and increased CAD incidence in humans.
|
16639078 |
2006 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
LHGDN |
The role of myeloperoxidase in the pathogenesis of coronary artery disease.
|
15507760 |
2004 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease.
|
15006595 |
2004 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the -463 G/A polymorphism of the MPO gene influences the risk of CAD.
|
11479475 |
2001 |